Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy

A review of cancer immunotherapy toxicity

(2020) Lucy Boyce Kennedy et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Pembrolizumab for Early Triple-Negative Breast Cancer

(2020) Peter Schmid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Circulating MicroRNAs and Extracellular Vesicle–Containing MicroRNAs as Response Biomarkers of Anti–programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Therapy in NSCLC

(2020) Takehito Shukuya et al.   Journal of Thoracic Oncology

A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma

(2020) Fathima Zumla Cader et al.   NATURE MEDICINE

Sequential ctDNA whole-exome sequencing in advanced lung adenocarcinoma with initial durable tumor response on immune checkpoint inhibitor and late progression

(2020) Etienne Giroux Leprieur et al.   Journal for ImmunoTherapy of Cancer

The Tumor and Host Immune Signature, and the Gut Microbiota as Predictive Biomarkers for Immune Checkpoint Inhibitor Response in Melanoma Patients

(2020) Katarzyna Tomela et al.   Life-Basel

PD-1/PD-L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway

(2019) Rui Zhao et al.   CELL PROLIFERATION

Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer

(2019) C G Kim et al.   ANNALS OF ONCOLOGY

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies

(2019) Dongxu Wang et al.   Journal of Hematology & Oncology

Research progress on the PI3K/AKT signaling pathway in gynecological cancer (Review)

(2019) Xiang Shi et al.   Molecular Medicine Reports

Immune profiling of pre- and post-treatment breast cancer tissues from the SWOG S0800 neoadjuvant trial

(2019) Xiaotong Li et al.   Journal for ImmunoTherapy of Cancer

Application of PD-1 Blockade in Cancer Immunotherapy

(2019) Xiaomo Wu et al.   Computational and Structural Biotechnology Journal

Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy

(2019) Heng-Huan Lee et al.   CANCER CELL

Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio in Outcome of Immune Checkpoint Inhibitors

(2019) Xianhe Xie et al.   CANCER INVESTIGATION

Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies

(2019) Hao Wang et al.   Journal of Hematology & Oncology

Recharacterizing Tumor-Infiltrating Lymphocytes by Single-Cell RNA Sequencing

(2019) Lei Zhang et al.   Cancer Immunology Research

Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma

(2019) Yi Zheng et al.   Journal for ImmunoTherapy of Cancer

Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma

(2019) Nicholas D. Klemen et al.   Journal for ImmunoTherapy of Cancer

Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Preexisting Autoimmune Disease: A Nationwide Multicenter Cohort Study

(2019) Alice Tison et al.   Arthritis & Rheumatology

PTEN Alterations as a Potential Mechanism for Tumor Cell Escape from PD-1/PD-L1 Inhibition

(2019) Cretella et al.   Cancers

Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors

(2019) Rachel Grosser et al.   CANCER CELL

Circulating microRNAs predict the response to anti-PD-1 therapy in non-small cell lung cancer

(2019) Jinshuo Fan et al.   GENOMICS

Beyond the Cell Surface: Targeting Intracellular Negative Regulators to Enhance T cell Anti-Tumor Activity

(2019) Sitaram et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

MicroRNAs that predict the effectiveness of anti-PD-1 therapies in patients with advanced melanoma

(2019) Satoshi Nakahara et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

TCR Repertoire Diversity of Peripheral PD-1+CD8+ T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer

(2019) Jiefei Han et al.   Cancer Immunology Research

Circulating microRNAs associated with prolonged overall survival in lung cancer patients treated with nivolumab

(2018) Ann Rita Halvorsen et al.   ACTA ONCOLOGICA

Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease

(2018) Noha Abdel-Wahab et al.   ANNALS OF INTERNAL MEDICINE

Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)

(2018) T R Cottrell et al.   ANNALS OF ONCOLOGY

Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer

(2018) Matthew D. Hellmann et al.   CANCER CELL

Mechanisms of Resistance to PD-1 and PD-L1 Blockade

(2018) Theodore S. Nowicki et al.   CANCER JOURNAL

Future of anti-PD-1/PD-L1 applications: Combinations with other therapeutic regimens

(2018) Mengjia Song et al.   Chinese Journal of Cancer Research

Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non–Small Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab

(2018) Brandon W. Higgs et al.   CLINICAL CANCER RESEARCH

CAR T-cell Therapy: A New Era in Cancer Immunotherapy

(2018) Miliotou N. Androulla et al.   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics

(2018) Margarita Udall et al.   Diagnostic Pathology

Inhibitors of the PD-1 Pathway in Tumor Therapy

(2018) Martin W. LaFleur et al.   JOURNAL OF IMMUNOLOGY

The PI3K/AKT signaling pathway in regulatory T-cell development, stability, and function

(2018) Saige L. Pompura et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers

(2018) Mohamed E. Salem et al.   MOLECULAR CANCER RESEARCH

High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy

(2018) Carsten Krieg et al.   NATURE MEDICINE

Immunotherapy of melanoma

(2018) Iwona Lugowska et al.   Wspolczesna Onkologia-Contemporary Oncology

Single Cell T Cell Receptor Sequencing: Techniques and Future Challenges

(2018) Marco De Simone et al.   Frontiers in Immunology

Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab

(2018) Mariaelena Capone et al.   Journal for ImmunoTherapy of Cancer

Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations

(2018) Jun Gong et al.   Journal for ImmunoTherapy of Cancer

Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA)

(2018) Patrick Danaher et al.   Journal for ImmunoTherapy of Cancer

Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations

(2018) Judith A. Seidel et al.   Frontiers in Oncology

Cancer immunotherapy with CAR-T cells – behold the future

(2018) Charlotte Graham et al.   CLINICAL MEDICINE

PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy

(2018) Fatemeh K. Dermani et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer

(2018) Muhammad Khan et al.   MEDICINE

Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors

(2018) Ming Yi et al.   Molecular Cancer

Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab

(2018) David R. Gandara et al.   NATURE MEDICINE

Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy

(2018) Anastasia Constantinidou et al.   PHARMACOLOGY & THERAPEUTICS

Drug response to PD-1/PD-L1 blockade: based on biomarkers

(2018) Qi Chen et al.   OncoTargets and Therapy

PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer

(2018) David Stenehjem et al.   OncoTargets and Therapy

Topography of cancer-associated immune cells in human solid tumors

(2018) Jakob Nikolas Kather et al.   eLife

Immune-related adverse events of immune checkpoint inhibitors: a brief review

(2018) G. Myers   Current Oncology

Predictive biomarkers of response for immune checkpoint inhibitors in non–small-cell lung cancer

(2018) Arsela Prelaj et al.   EUROPEAN JOURNAL OF CANCER

Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer

(2018) A. N. Niemeijer et al.   Nature Communications

Effectiveness and safety of PD-1/PD-L1 or CTLA4 inhibitors combined with chemotherapy as a first-line treatment for lung cancer: A meta-analysis

(2018) Kaikai Shen et al.   Journal of Thoracic Disease

CTLA-4 and PD-1 Control of T-Cell Motility and Migration: Implications for Tumor Immunotherapy

(2018) Monika C. Brunner-Weinzierl et al.   Frontiers in Immunology

Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma

(2018) Tomas Jelinek et al.   Frontiers in Immunology

Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade

(2018) Wassim Abida et al.   JAMA Oncology

Immunotherapy in SCLC: Exceptional Clinical Benefit and Abscopal Pneumonitis After Radiotherapy

(2018) Laura Bonanno et al.   Journal of Thoracic Oncology

Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells

(2017) Varun Sasidharan Nair et al.   IMMUNOLOGY AND CELL BIOLOGY

Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy

(2017) Jarushka Naidoo et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical trials of CAR-T cells in China

(2017) Bingshan Liu et al.   Journal of Hematology & Oncology

Dabrafenib plus trametinib in patients with BRAF V600 -mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial

(2017) Michael A Davies et al.   LANCET ONCOLOGY

Implications of the tumor immune microenvironment for staging and therapeutics

(2017) Janis M Taube et al.   MODERN PATHOLOGY

Tumor Mutational Burden and Response Rate to PD-1 Inhibition

(2017) Mark Yarchoan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients

(2017) Alice O. Kamphorst et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients

(2017) V. Gopalakrishnan et al.   SCIENCE

Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

(2017) Bertrand Routy et al.   SCIENCE

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PDL1 blockade

(2017) Jie Bai et al.   Oncotarget

PD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a dose-independent manner: a meta-analysis

(2017) Jiaying Wu et al.   Scientific Reports

Multiple treatment comparison of seven new drugs for patients with advanced malignant melanoma: a systematic review and health economic decision model in a Norwegian setting

(2017) Eva Pike et al.   BMJ Open

PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome

(2017) Hashem O. Alsaab et al.   Frontiers in Pharmacology

Cancer prevention from the perspective of global cancer burden patterns

(2017) Hiroki Nagai et al.   Journal of Thoracic Disease

The Future of Immunotherapy: A 20-Year Perspective

(2017) David C. Wraith   Frontiers in Immunology

Primary Immunodeficiency Diseases: Current and Emerging Therapeutics

(2017) Beatriz E. Marciano et al.   Frontiers in Immunology

PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma

(2017) Jan Budczies et al.   OncoImmunology

Immunotherapy and tumor microenvironment

(2016) Haidong Tang et al.   CANCER LETTERS

Mass Cytometry: Single Cells, Many Features

(2016) Matthew H. Spitzer et al.   CELL

Genomic Approaches to Understanding Response and Resistance to Immunotherapy

(2016) D. A. Braun et al.   CLINICAL CANCER RESEARCH

Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab

(2016) A. Martens et al.   CLINICAL CANCER RESEARCH

Immune-related adverse events with immune checkpoint blockade: a comprehensive review

(2016) J.M. Michot et al.   EUROPEAN JOURNAL OF CANCER

Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy

(2016) Lars Hofmann et al.   EUROPEAN JOURNAL OF CANCER

Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges

(2016) Chrisann Kyi et al.   Immunotherapy

Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma

(2016) Katharina C. Kähler et al.   JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT

Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors

(2016) Ludmila Danilova et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

(2016) Shohei Koyama et al.   Nature Communications

Pembrolizumab for the treatment of advanced melanoma

(2016) Michael C. Burns et al.   Expert Opinion on Orphan Drugs

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies

(2015) J. Naidoo et al.   ANNALS OF ONCOLOGY

High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma

(2015) J. Zaragoza et al.   BRITISH JOURNAL OF DERMATOLOGY

Classifying Cancers Based on T-cell Infiltration and PD-L1

(2015) Michele W.L. Teng et al.   CANCER RESEARCH

Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy

(2015) Xiangjiao Meng et al.   CANCER TREATMENT REVIEWS

Oral immunotherapy for food allergy: mechanisms and role in management

(2015) A. Nowak-Węgrzyn et al.   CLINICAL AND EXPERIMENTAL ALLERGY

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma

(2015) Kathleen M. Mahoney et al.   CLINICAL THERAPEUTICS

Microsatellite Instability Testing and Its Role in the Management of Colorectal Cancer

(2015) Hisato Kawakami et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Combination cancer immunotherapy and new immunomodulatory targets

(2015) Kathleen M. Mahoney et al.   NATURE REVIEWS DRUG DISCOVERY

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti–PD-1–Related Pneumonitis during Cancer Immunotherapy

(2015) Mizuki Nishino et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer

(2015) Christine Mall et al.   OncoImmunology

Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma

(2015) Heinz Läubli et al.   Journal for ImmunoTherapy of Cancer

The Programmed Death-1 Immune-Suppressive Pathway: Barrier to Antitumor Immunity

(2014) Suzanne Ostrand-Rosenberg et al.   JOURNAL OF IMMUNOLOGY

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

(2014) Matthew M. Gubin et al.   NATURE

Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

(2014) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Perceptions of Cancer Risk and Cause of Cancer Risk in Korean Adults

(2014) Su Yeon Kye et al.   Cancer Research and Treatment

Opportunistic infections in patients treated with immunotherapy for cancer

(2014) Chrisann Kyi et al.   Journal for ImmunoTherapy of Cancer

Long-term survival after adoptive bone marrow T cell therapy of advanced metastasized breast cancer: follow-up analysis of a clinical pilot trial

(2013) Christoph Domschke et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Programmed Death Ligand 2 in Cancer-Induced Immune Suppression

(2012) Esdy N. Rozali et al.   Clinical & Developmental Immunology

Immunotherapy for Primary Immunodeficiency Diseases

(2012) Philip Wood   MEDICAL CLINICS OF NORTH AMERICA

Auto T cells expressing chimeric antigen receptor derived from auto antibody might be a new treatment for osteosarcoma

(2012) Pan Weibo et al.   MEDICAL HYPOTHESES

MicroRNA-548 down-regulates host antiviral response via direct targeting of IFN-λ1

(2012) Yongkui Li et al.   Protein & Cell

The role of the PD-1 pathway in autoimmunity and peripheral tolerance

(2011) Brian T. Fife et al.   Annals of the New York Academy of Sciences

The PD-1 pathway in tolerance and autoimmunity

(2010) Loise M. Francisco et al.   IMMUNOLOGICAL REVIEWS

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

(2010) M. A. Curran et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PD-1 signaling in primary T cells

(2009) James L. Riley   IMMUNOLOGICAL REVIEWS

Treatment of advanced metastasized breast cancer with bone marrow-derived tumour-reactive memory T cells: a pilot clinical study

(2008) Florian Schuetz et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Coordinated Regulation of Cell Cycle Transcripts by p53-Inducible microRNAs, miR-192 and miR-215

(2008) S. A. Georges et al.   CANCER RESEARCH